The table shows that resmetirom is a small (molecular weight about 600 g/mol), non-iodinated THR- agonist administered once daily as an oral tablet, while semaglutide is a large (about 4 kDa) GLP-1 peptide designed for once-weekly subcutaneous injection or, with SNAC enhancement, once-daily oral administration
Bring up concerns about long-term treatment planning, including financial considerations, insurance coverage changes, or life circumstances affecting your ability to continue therapy
This means the volume you inject for the same dose can differ significantly
In contrast, the passive membrane permeation of small molecules and macrocyclic peptides is reasonably well developed and understood, to the point where computational models are now able to predict the permeability of small molecule drugs 6,7 and macrocyclic peptides with predominantly hydrophobic side chains 8 , especially when coupled with continuous constant p H molecular dynamics (C p HMD) models for small molecule drugs 6 (Fig
In addition, Eli Lilly has several follow-on patents granted for delivery devices, formulations, and methods-of-treatment
